Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Express Scripts
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

SANCTURA XR Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Sanctura Xr patents expire, and what generic alternatives are available?

Sanctura Xr is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in SANCTURA XR is trospium chloride. There are sixteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the trospium chloride profile page.

US ANDA Litigation and Generic Entry Outlook for Sanctura Xr

A generic version of SANCTURA XR was launched as trospium chloride by GLENMARK GENERICS on December 12th, 2019.

Drug patent expirations by year for SANCTURA XR
Recent Clinical Trials for SANCTURA XR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Astellas Scientific & Medical Affairs, Inc.N/A
AllerganPhase 1
AllerganPhase 4

See all SANCTURA XR clinical trials

Recent Litigation for SANCTURA XR

Identify potential future generic entrants

District Court Litigation
Case NameDate
SUPERNUS PHARMACEUTICALS, INC. v. PAR PHARMACEUTICAL COMPANIES, INC.2015-01-16
Allergan Inc. v. Watson Laboratories, Inc.-Florida

See all SANCTURA XR litigation

Synonyms for SANCTURA XR
[(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate chloride
[(1S,5R)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate;chloride
[(1S,5R)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-oxidanyl-2,2-diphenyl-ethanoate chloride
1001323-19-8
10405-02-4
1E6682427E
2-hydroxy-2,2-diphenylacetic acid [(1S,5R)-3-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]yl] ester chloride
3-((hydroxydiphenylacetyl)oxy)-spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium chloride
3alpha-Hydroxyspiro(1alphaH,5alphaH-nortropane-8,1'-pyrrolidinium) chloride benzilate
8-alpha-Benziloyloxy-6,10-ethano-5-azoniaspiro(4.5)decane chloride
A800884
AB0000782
AB2000646
AC-4235
AC1NR4ST
AKOS015833209
API0004533
AS Xvii
Azoniaspiro Compound XVII
Azoniaspiro(3-alpha-benziloyloxy-nortropan-8,1'-pyrrolidine)-chloride
B-1868
BC209629
BCP0726000291
BCP23426
CAS-10405-02-4
CHEMBL3084748
Chlorure de trospium
Chlorure de trospium [INN-French]
Cloruro de trospio
Cloruro de trospio [INN-Spanish]
CS-2572
DSSTox_CID_3724
DSSTox_GSID_23724
DSSTox_RID_77166
DTXSID7023724
EINECS 233-875-4
FT-0636699
HMS3656C16
HY-B0461
IP631
Keptan
MolPort-005-935-494
NCGC00167438-01
NCGC00167438-02
Relaspium
RVCSYOQWLPPAOA-QKYUOBHYSA-M
s2549
Sanctura
Santura
SCHEMBL13836646
SCHEMBL25785
Spasmex
Spasmo 3
Spasmo-lyt
Spiro (8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-((hydroxydiphenylacetyl)oxy)-, chloride, (1alpha, 3beta, 5alpha)
Spiro(1-alpha-H,5-alpha-H-nortropane-8,1'-pyrrolidinium), 3-alpha-hydroxy-, chloride, benzilate
Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium, 3-((hydroxydiphenylacetyl)oxy)-, chloride, (1alpha,3beta,5alpha)-
Spiro[8azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5);Spiro[8azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium], 3-[(hydroxydiphenylacetyl)oxy]-, chloride, (1, 3, 5)
ST24050330
SW219146-1
Tox21_112442
Tox21_112442_1
Trospii chloridum
Trospii chloridum [INN-Latin]
Trospium (chloride)
trospium chloride
Trospium chloride (Sanctura)
Trospium chloride [USAN:USP:INN:BAN:JAN]
Trospium Cl
Trospiumchlorid
UNII-1E6682427E
Uraplex
W-108827
Paragraph IV (Patent) Challenges for SANCTURA XR
Tradename Dosage Ingredient NDA Submissiondate
SANCTURA XR CAPSULE, EXTENDED RELEASE;ORAL trospium chloride 022103 2009-03-02

US Patents and Regulatory Information for SANCTURA XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan SANCTURA XR trospium chloride CAPSULE, EXTENDED RELEASE;ORAL 022103-001 Aug 3, 2007 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Merck
Medtronic
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.